Objective The in-use stability of lyophilised oxaliplatin and lactose formulation diluted in 5% dextrose injection was studied to assess the feasibility of preparing oxaliplatin solutions in advance in hospital pharmacy settings. The available in-use stability data of oxaliplatin solutions are based on infusions prepared with 5mg/mL concentrated solutions. Methods Oxaliplatin solutions of 0.5mg/mL (n=6), 0.7mg/mL (n=6) and 5mg/mL (n=6) were prepared using oxaliplatin 100mg powder and 100mL of 5% dextrose injection in polyolefin infusion bags. The samples were stored at 2-8 degrees C without light protection and were analysed at 1, 2, 4, 7, 14, 21 and 60days. The in-use stability was studied using the high-performance liquid chromatography stability indicating method. The solutions were checked for colour, particulate matter and pH. Results The mean concentrations of 0.5mg/mL and 0.7mg/mL oxaliplatin solutions decreased to less than 90%, within 7 and 14days, respectively, compared with the initial drug concentration in the solutions. The concentrated solution of 5mg/mL oxaliplatin was stable (over 90%) for at least 60days. The colour, clarity and pH remained unchanged throughout the storage period. Sterility and apirogenicity standards, as defined in the European Pharmacopoeia, were met. Conclusion Infusion solutions of oxaliplatin prepared with lyophilised oxaliplatin 100mg, 0.5mg/mL and 0.7mg/mL which were stored in polyolefin infusion bags, were chemically unstable within 7days and 14days, respectively, at 2-8 degrees C without light protection. The poor stability of the diluted solutions does not allow oxaliplatin to be prepared in advance and stored in pharmacy departments.

Stability of lyophilised oxaliplatin formulation in polyolefin infusion bags containing 5% dextrose injection

MAZZI, ULDERICO;MORPURGO, MARGHERITA;FRANCESCHINIS, ERICA;REALDON, NICOLA
2014

Abstract

Objective The in-use stability of lyophilised oxaliplatin and lactose formulation diluted in 5% dextrose injection was studied to assess the feasibility of preparing oxaliplatin solutions in advance in hospital pharmacy settings. The available in-use stability data of oxaliplatin solutions are based on infusions prepared with 5mg/mL concentrated solutions. Methods Oxaliplatin solutions of 0.5mg/mL (n=6), 0.7mg/mL (n=6) and 5mg/mL (n=6) were prepared using oxaliplatin 100mg powder and 100mL of 5% dextrose injection in polyolefin infusion bags. The samples were stored at 2-8 degrees C without light protection and were analysed at 1, 2, 4, 7, 14, 21 and 60days. The in-use stability was studied using the high-performance liquid chromatography stability indicating method. The solutions were checked for colour, particulate matter and pH. Results The mean concentrations of 0.5mg/mL and 0.7mg/mL oxaliplatin solutions decreased to less than 90%, within 7 and 14days, respectively, compared with the initial drug concentration in the solutions. The concentrated solution of 5mg/mL oxaliplatin was stable (over 90%) for at least 60days. The colour, clarity and pH remained unchanged throughout the storage period. Sterility and apirogenicity standards, as defined in the European Pharmacopoeia, were met. Conclusion Infusion solutions of oxaliplatin prepared with lyophilised oxaliplatin 100mg, 0.5mg/mL and 0.7mg/mL which were stored in polyolefin infusion bags, were chemically unstable within 7days and 14days, respectively, at 2-8 degrees C without light protection. The poor stability of the diluted solutions does not allow oxaliplatin to be prepared in advance and stored in pharmacy departments.
2014
Inglese
21
1
45
48
4
Internazionale
anonymous
Medical Research, General Topics covers a wide array of topics in medical and biomedical research, with a specific emphasis on human disease, human tissues, and all levels of research into the pathogenesis of clinically significant conditions. Specific medical fields that are characterized by the inclusion of material from several other specializations are also covered here; these include general and internal medicine, tropical medicine, pediatrics, gerontology, epidemiology, and public health. Resources dealing with specific clinical interventions are excluded and are placed in the Medical Research: Diagnosis & Treatment category. Resources that emphasize the specific disease types, or specific systems affected are also excluded and are categorized according to the pathogen or system pathophysiology.
Pharmacology & Toxicology includes all aspects of pharmacology, toxicology, and pharmaceutics. Of particular importance are cellular and molecular pharmacology, drug design and metabolism, mechanisms of drug action, drug delivery, natural products, xenobiotics, and clinical therapeutics. Toxicology coverage considers cellular and molecular effects of harmful substances, environmental toxicology, occupational exposure, and clinical toxicology. Drug bulletins, drug updates, and pharmaceutical newsletters are excluded as are resources on pharmaceutical engineering. Medicinal chemistry, or synthesis and chemical analysis of pharmaceuticals are placed in the Chemistry & Analysis category.
The Chemistry category includes resources that are general in nature and cover a broad spectrum of topics in the chemical sciences. Resources specifically covering analytical chemistry, inorganic and nuclear chemistry, organic chemistry, physical chemistry, and polymer science will be placed in those particular categories. Miscellaneous and applied chemistry resources may be placed in this category when not appropriate for specific subfields in chemistry.
ITALIA
no
none
M. P., Trojniak; Mazzi, Ulderico; A. C., Palozzo; Morpurgo, Margherita; Franceschinis, Erica; Realdon, Nicola
01 CONTRIBUTO IN RIVISTA::01.01 - Articolo in rivista
info:eu-repo/semantics/article
6
262
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/2683654
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
  • OpenAlex 2
social impact